Epilepsy Drugs Market by Country (US, UK, France, etc), Drugs (Vimpat, Keppra, Sabril, Onfi, etc), Treatment Drugs Generation (First, Second, Third), Companies & Forecast
Epilepsy is a chronic disease in which patient’s brain activities become abnormal due to seizures. Seizure is an unexpected rush of electrical activity in the brain. Seizure is categorized by two types - generalized seizures and focal or partial seizures. Generalized seizures affect the whole brain whereas focal or partial seizures affect just one part of the brain. Global epilepsy drugs market is expected to cross US$ 9 Billion landmark by 2025.
Epilepsy can develop in both males and females of all races, ethnic backgrounds and ages. It affects around 65 Million people globally. United States has around 3.4 Million epilepsy patients; among them around 470 Thousands are children. Epilepsy prevalence varies across various parts of the world. At present, nearly one-third of the total patients are suffering from uncontrollable seizures and are not able to get treatment because no available treatment works for them.
The factors that are driving the global Epilepsy drug market are increasing epilepsy prevalence, growing patient awareness programs, government funding and drugs reimbursement options in European & American countries. Recently, anti-epilepsy drugs Epidiolex approvals for pediatric epilepsies, namely Lennox-Gastaut syndrome and Dravet syndrome in United States will also help in the growth of Epilepsy drug market during the forecast period as well.
Renub Research report titled “Epilepsy Drugs Market by Country (United States, United Kingdom, France, Germany, Italy, Spain, India, China, Japan), Drugs [(Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089)], Treatment Drugs Generation (First, Second, Third), Company (Eisai Co., Ltd, UCB Inc., H. Lundbeck A/S, GW Pharmaceuticals Plc.) & Forecast” provides a complete analysis of Global Epilepsy Drugs Market. This report also covers all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.
By Country – United States is Dominating Global Epilepsy Drugs Market
The report studies the market of the following countries: United States, United Kingdom, France, Germany, Italy, Spain, India, China and Japan. United States is dominating global epilepsy drugs market. Its share is expected to grow in the years to come due to better healthcare support system, growing awareness and increasing per capita healthcare expenditure.
By Drugs – Vimpat (Lacosamide), Keppra (Levetiracetam) and Epidiolex are playing a significant role
The report studies the market of the following drugs: Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089). At present, Vimpat (Lacosamide) and Keppra (Levetiracetam) are playing the significant role for the epilepsy treatment. Epidiolex has a bright future ahead.
By Drugs Category – Second and Third Generation Plays the Significant Role
In this report, we have categorized the epilepsy drugs market into three generation; First Generation, Second Generation, Third Generation. It is anticipated that second and third generation plays the significant role in the global epilepsy drugs market during the forecast period of 2019-2025.
Company Analysis
Eisai Co., Ltd, UCB Inc., H. Lundbeck A/S and GW Pharmaceuticals Plc. are some of the top companies that deal efficiently in epilepsy business globally. These companies have been studied thoroughly in the report.
Countries covered in this report are:
Epilepsy can develop in both males and females of all races, ethnic backgrounds and ages. It affects around 65 Million people globally. United States has around 3.4 Million epilepsy patients; among them around 470 Thousands are children. Epilepsy prevalence varies across various parts of the world. At present, nearly one-third of the total patients are suffering from uncontrollable seizures and are not able to get treatment because no available treatment works for them.
The factors that are driving the global Epilepsy drug market are increasing epilepsy prevalence, growing patient awareness programs, government funding and drugs reimbursement options in European & American countries. Recently, anti-epilepsy drugs Epidiolex approvals for pediatric epilepsies, namely Lennox-Gastaut syndrome and Dravet syndrome in United States will also help in the growth of Epilepsy drug market during the forecast period as well.
Renub Research report titled “Epilepsy Drugs Market by Country (United States, United Kingdom, France, Germany, Italy, Spain, India, China, Japan), Drugs [(Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089)], Treatment Drugs Generation (First, Second, Third), Company (Eisai Co., Ltd, UCB Inc., H. Lundbeck A/S, GW Pharmaceuticals Plc.) & Forecast” provides a complete analysis of Global Epilepsy Drugs Market. This report also covers all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.
By Country – United States is Dominating Global Epilepsy Drugs Market
The report studies the market of the following countries: United States, United Kingdom, France, Germany, Italy, Spain, India, China and Japan. United States is dominating global epilepsy drugs market. Its share is expected to grow in the years to come due to better healthcare support system, growing awareness and increasing per capita healthcare expenditure.
By Drugs – Vimpat (Lacosamide), Keppra (Levetiracetam) and Epidiolex are playing a significant role
The report studies the market of the following drugs: Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089). At present, Vimpat (Lacosamide) and Keppra (Levetiracetam) are playing the significant role for the epilepsy treatment. Epidiolex has a bright future ahead.
By Drugs Category – Second and Third Generation Plays the Significant Role
In this report, we have categorized the epilepsy drugs market into three generation; First Generation, Second Generation, Third Generation. It is anticipated that second and third generation plays the significant role in the global epilepsy drugs market during the forecast period of 2019-2025.
Company Analysis
Eisai Co., Ltd, UCB Inc., H. Lundbeck A/S and GW Pharmaceuticals Plc. are some of the top companies that deal efficiently in epilepsy business globally. These companies have been studied thoroughly in the report.
Countries covered in this report are:
- United States
- United Kingdom
- France
- Germany
- Italy
- Spain
- India
- China
- Japan
- First Generation
- Second Generation
- Third Generation
- Vimpat (Lacosamide)
- Keppra (Levetiracetam)
- Sabril (Vigabatrin)
- Onfi (Clobazam)
- Fycompa
- Briviact (Brivaracetam)
- Epidiolex
- Cenobamate (YKP3089)
- Eisai Co., Ltd
- UCB Inc.
- H. Lundbeck A/S
- GW Pharmaceuticals Plc.
1. INTRODUCTION
1.1 Market Definition
1.2 Currency Conversion
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. GLOBAL EPILEPSY DRUGS MARKET (2013 – 2025)
5. MARKET SHARE – GLOBAL EPILEPSY DRUGS (2013 – 2025)
5.1 By Country
5.2 By Drugs Category
5.3 By Drugs
6. COUNTRY - GLOBAL EPILEPSY DRUGS MARKET ANALYSIS (2013 – 2025)
6.1 United States
6.2 United Kingdom
6.3 France
6.4 Germany
6.5 Italy
6.6 Spain
6.7 India
6.8 China
6.9 Japan
7. BY DRUGS CATEGORY - GLOBAL EPILEPSY DRUGS MARKET ANALYSIS (2013 – 2025)
7.1 First Generation
7.2 Second Generation
7.3 Third Generation
8. BY DRUGS - GLOBAL EPILEPSY DRUGS MARKET ANALYSIS (2013 – 2025)
8.1 Vimpat (Lacosamide)
8.2 Keppra (Levetiracetam)
8.3 Sabril (Vigabatrin)
8.4 Onfi (Clobazam)
8.5 Fycompa
8.6 Briviact (Brivaracetam)
8.7 Epidiolex
8.8 Cenobamate (YKP3089)
9. GROWTH DRIVERS
9.1 Growing Awareness Programs Worldwide
9.2 Presence of Promising Pipeline for Epilepsy Therapeutics
10. CHALLENGES
10.1 New Restrictions on Epilepsy Drug
10.2 High Cost of Antiepileptic Drugs
11. EISAI CO., LTD.
11.1 Company Overview
11.2 Initiatives/Activities
11.2.1 Point
11.2.2 Point
11.2.3 Point
11.3 Financial Insight
12. UCB INC.
12.1 Company Overview
12.2 Initiatives/Activities
12.2.1 Point
12.2.2 Point
12.2.3 Point
12.2.4 Point
12.3 Financial Insight
13. H. LUNDBECK A/S
13.1 Company Overview
13.2 Initiatives/Activities
13.2.1 Point
13.2.2 Point
13.2.3 Point
13.3 Financial Insight
14. GW PHARMACEUTICALS PLC.
14.1 Company Overview
14.2 Initiatives/Activities
14.2.1 Point
14.2.2 Point
14.3 Financial Insight
1.1 Market Definition
1.2 Currency Conversion
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. GLOBAL EPILEPSY DRUGS MARKET (2013 – 2025)
5. MARKET SHARE – GLOBAL EPILEPSY DRUGS (2013 – 2025)
5.1 By Country
5.2 By Drugs Category
5.3 By Drugs
6. COUNTRY - GLOBAL EPILEPSY DRUGS MARKET ANALYSIS (2013 – 2025)
6.1 United States
6.2 United Kingdom
6.3 France
6.4 Germany
6.5 Italy
6.6 Spain
6.7 India
6.8 China
6.9 Japan
7. BY DRUGS CATEGORY - GLOBAL EPILEPSY DRUGS MARKET ANALYSIS (2013 – 2025)
7.1 First Generation
7.2 Second Generation
7.3 Third Generation
8. BY DRUGS - GLOBAL EPILEPSY DRUGS MARKET ANALYSIS (2013 – 2025)
8.1 Vimpat (Lacosamide)
8.2 Keppra (Levetiracetam)
8.3 Sabril (Vigabatrin)
8.4 Onfi (Clobazam)
8.5 Fycompa
8.6 Briviact (Brivaracetam)
8.7 Epidiolex
8.8 Cenobamate (YKP3089)
9. GROWTH DRIVERS
9.1 Growing Awareness Programs Worldwide
9.2 Presence of Promising Pipeline for Epilepsy Therapeutics
10. CHALLENGES
10.1 New Restrictions on Epilepsy Drug
10.2 High Cost of Antiepileptic Drugs
11. EISAI CO., LTD.
11.1 Company Overview
11.2 Initiatives/Activities
11.2.1 Point
11.2.2 Point
11.2.3 Point
11.3 Financial Insight
12. UCB INC.
12.1 Company Overview
12.2 Initiatives/Activities
12.2.1 Point
12.2.2 Point
12.2.3 Point
12.2.4 Point
12.3 Financial Insight
13. H. LUNDBECK A/S
13.1 Company Overview
13.2 Initiatives/Activities
13.2.1 Point
13.2.2 Point
13.2.3 Point
13.3 Financial Insight
14. GW PHARMACEUTICALS PLC.
14.1 Company Overview
14.2 Initiatives/Activities
14.2.1 Point
14.2.2 Point
14.3 Financial Insight
LIST OF FIGURES:
Figure 4 1: Global - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 4 2: Global – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 5 1: Global - Epilepsy Drugs Market Country Share (Percent), 2013 – 2018
Figure 5 2: Global – Forecast for Epilepsy Drugs Market Country Share (Percent), 2019 – 2025
Figure 5 3: Global - Epilepsy Drugs Category Market Share (Percent), 2013 – 2018
Figure 5 4: Global – Forecast for Epilepsy Drugs Category Market Share (Percent), 2019 – 2025
Figure 5 5: Global - Epilepsy Drugs Market Share (Percent), 2013 – 2018
Figure 5 6: Global – Forecast for Epilepsy Drugs Market Share (Percent), 2019 – 2025
Figure 6 1: United States - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 2: United States – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 3: United Kingdom - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 4: United Kingdom – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 5: France - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 6: France – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 7: Germany - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 8: Germany – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 9: Italy - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 10: Italy – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 11: Spain - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 12: Spain – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 13: India - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 14: India – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 15: China - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 16: China – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 17: Japan - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 18: Japan – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 7 1: Global - First Generation Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 7 2: Global – Forecast for First Generation Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 7 3: Global - Second Generation Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 7 4: Global – Forecast for Second Generation Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 7 5: Global - Third Generation Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 7 6: Global – Forecast for Third Generation Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 8 1: Global Epilepsy Drugs Market – Vimpat (Lacosamide) Sales (Million US$), 2013 – 2018
Figure 8 2: Global Epilepsy Drugs Market – Forecast for Vimpat (Lacosamide) Sales (Million US$), 2019 – 2025
Figure 8 3: Global Epilepsy Drugs Market – Keppra (Levetiracetam) Sales (Million US$), 2013 – 2018
Figure 8 4: Global Epilepsy Drugs Market – Forecast for Keppra (Levetiracetam) Sales (Million US$), 2019 – 2025
Figure 8 5: Global Epilepsy Drugs Market – Sabril (Vigabatrin) Sales (Million US$), 2013 – 2018
Figure 8 6: Global Epilepsy Drugs Market – Forecast for Sabril (Vigabatrin) Sales (Million US$), 2019 – 2025
Figure 8 7: Global Epilepsy Drugs Market – Onfi (Clobazam) Sales (Million US$), 2013 – 2018
Figure 8 8: Global Epilepsy Drugs Market – Forecast for Onfi (Clobazam) Sales (Million US$), 2019 – 2025
Figure 8 9: Global Epilepsy Drugs Market – Fycompa Sales (Million US$), 2015 – 2018
Figure 8 10: Global Epilepsy Drugs Market – Forecast for Fycompa Sales (Million US$), 2019 – 2025
Figure 8 11: Global Epilepsy Drugs Market – Briviact (Brivaracetam) Sales (Million US$), 2016 – 2018
Figure 8 12: Global Epilepsy Drugs Market – Forecast for Briviact (Brivaracetam) Sales (Million US$), 2019 – 2025
Figure 8 13: Global Epilepsy Drugs Market – Present & Forecast for Epidiolex Sales (Million US$), 2018 – 2025
Figure 8 14: Global Epilepsy Drugs Market – Forecast for Cenobamate (YKP3089) Sales (Million US$), 2019 – 2025
Figure 9 1: Global - Epilepsy Therapeutics Studies (Number), November 2018
Figure 11 1: Eisai Co., Ltd – Global Sales (Million US$), 2013 – 2018
Figure 11 2: Eisai Co., Ltd – Forecast for Global Sales (Million US$), 2019 – 2025
Figure 12 1: UCB Inc. – Global Sales (Million US$), 2013 – 2018
Figure 12 2: UCB Inc. – Forecast for Global Sales (Million US$), 2019 – 2025
Figure 13 1: Lundbeck – Global Sales (Million US$), 2013 – 2018
Figure 13 2: Lundbeck – Forecast for Global Sales (Million US$), 2019 – 2025
Figure 14 1: GW Pharmaceuticals – Global Revenue (Million US$), 2013 – 2018
Figure 14 2: GW Pharmaceuticals – Forecast for Global Revenue (Million US$), 2019 – 2025
Figure 4 1: Global - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 4 2: Global – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 5 1: Global - Epilepsy Drugs Market Country Share (Percent), 2013 – 2018
Figure 5 2: Global – Forecast for Epilepsy Drugs Market Country Share (Percent), 2019 – 2025
Figure 5 3: Global - Epilepsy Drugs Category Market Share (Percent), 2013 – 2018
Figure 5 4: Global – Forecast for Epilepsy Drugs Category Market Share (Percent), 2019 – 2025
Figure 5 5: Global - Epilepsy Drugs Market Share (Percent), 2013 – 2018
Figure 5 6: Global – Forecast for Epilepsy Drugs Market Share (Percent), 2019 – 2025
Figure 6 1: United States - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 2: United States – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 3: United Kingdom - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 4: United Kingdom – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 5: France - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 6: France – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 7: Germany - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 8: Germany – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 9: Italy - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 10: Italy – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 11: Spain - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 12: Spain – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 13: India - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 14: India – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 15: China - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 16: China – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 6 17: Japan - Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 6 18: Japan – Forecast for Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 7 1: Global - First Generation Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 7 2: Global – Forecast for First Generation Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 7 3: Global - Second Generation Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 7 4: Global – Forecast for Second Generation Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 7 5: Global - Third Generation Epilepsy Drugs Market (Million US$), 2013 – 2018
Figure 7 6: Global – Forecast for Third Generation Epilepsy Drugs Market (Million US$), 2019 – 2025
Figure 8 1: Global Epilepsy Drugs Market – Vimpat (Lacosamide) Sales (Million US$), 2013 – 2018
Figure 8 2: Global Epilepsy Drugs Market – Forecast for Vimpat (Lacosamide) Sales (Million US$), 2019 – 2025
Figure 8 3: Global Epilepsy Drugs Market – Keppra (Levetiracetam) Sales (Million US$), 2013 – 2018
Figure 8 4: Global Epilepsy Drugs Market – Forecast for Keppra (Levetiracetam) Sales (Million US$), 2019 – 2025
Figure 8 5: Global Epilepsy Drugs Market – Sabril (Vigabatrin) Sales (Million US$), 2013 – 2018
Figure 8 6: Global Epilepsy Drugs Market – Forecast for Sabril (Vigabatrin) Sales (Million US$), 2019 – 2025
Figure 8 7: Global Epilepsy Drugs Market – Onfi (Clobazam) Sales (Million US$), 2013 – 2018
Figure 8 8: Global Epilepsy Drugs Market – Forecast for Onfi (Clobazam) Sales (Million US$), 2019 – 2025
Figure 8 9: Global Epilepsy Drugs Market – Fycompa Sales (Million US$), 2015 – 2018
Figure 8 10: Global Epilepsy Drugs Market – Forecast for Fycompa Sales (Million US$), 2019 – 2025
Figure 8 11: Global Epilepsy Drugs Market – Briviact (Brivaracetam) Sales (Million US$), 2016 – 2018
Figure 8 12: Global Epilepsy Drugs Market – Forecast for Briviact (Brivaracetam) Sales (Million US$), 2019 – 2025
Figure 8 13: Global Epilepsy Drugs Market – Present & Forecast for Epidiolex Sales (Million US$), 2018 – 2025
Figure 8 14: Global Epilepsy Drugs Market – Forecast for Cenobamate (YKP3089) Sales (Million US$), 2019 – 2025
Figure 9 1: Global - Epilepsy Therapeutics Studies (Number), November 2018
Figure 11 1: Eisai Co., Ltd – Global Sales (Million US$), 2013 – 2018
Figure 11 2: Eisai Co., Ltd – Forecast for Global Sales (Million US$), 2019 – 2025
Figure 12 1: UCB Inc. – Global Sales (Million US$), 2013 – 2018
Figure 12 2: UCB Inc. – Forecast for Global Sales (Million US$), 2019 – 2025
Figure 13 1: Lundbeck – Global Sales (Million US$), 2013 – 2018
Figure 13 2: Lundbeck – Forecast for Global Sales (Million US$), 2019 – 2025
Figure 14 1: GW Pharmaceuticals – Global Revenue (Million US$), 2013 – 2018
Figure 14 2: GW Pharmaceuticals – Forecast for Global Revenue (Million US$), 2019 – 2025
